Comparing two surgical methods for advanced gastric cancer treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial compares the effectiveness of partial versus total omentectomy during minimally invasive distal gastrectomy for patients with advanced gastric cancer. The study aims to determine whether total omentectomy, which involves complete removal of the greater omentum, provides any significant oncological benefits compared to partial omentectomy, while also assessing the associated risks and complications. By evaluating surgical outcomes, the trial seeks to establish the best approach for ensuring patient safety and effective cancer treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven adenocarcinoma of the stomach
* Age between 20 to 85 years old
* ECOG PS 0-1, ASA class I-III
* Endoscopically Borrmann type I, II, III
* Clinical T3 and T4a tumors with or without regional lymph node metastases (cT3N0M0\~T4aN3M0)
* Capable of minimal invasive radical subtotal gastrectomy with R0 resection in preoperative examinations
* Patients who signed an written consent form approved by the Institutional Review Board(IRB) after receiving sufficient explanations of the contents of the clinical trial
* Domestic patients who are able to follow up for 3 years after surgery

Exclusion Criteria:

* Confirmed distant metastasis in preoperative examinations
* Confirmed metastasis in abdominal cavity or distant organs during surgery
* Confirmed no infiltration of the serosa layer or unable to confirm the tumor location during surgery (sT1-2)
* Confirmed invasion of surrounding organs (sT4b)
* History of previous gastrectomy or greater omentum related surgery
* Patients who underwent preoperative treatment (chemotherapy, radiotherapy, or endoscopic submucosal dissection) for recently diagnosed gastric cancer
* Synchronous or metachronous malignancies, which underwent surgery, chemotherapy or radiotherapy within 5 years
* Patients judged to be inappropriate for the study by the physician. (ex. Pregnancy)
* Patients refused to participate after random assignment
* Surgery is not performed until 30 days after consenting to participate
* Patients who has participated in another on-going clinical trial, which is related surgical procedures and survival.

Where it's running

• GangnamSeverance Hospital
  Seoul, South Korea Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• CG-7321: a first-in-human test in advanced solid tumors

  We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.

  Recruiting at 4 sites Phase 1 Chengdu Cynogen Bio-pharmaceutical Tech. Co., Ltd. · Fuzhou, Fujian and 3 other locations · NCT07923214

• Neoadjuvant trastuzumab, durvalumab, and FLOT for HER2-positive gastric or GEJ cancer

  This study tests a pre-surgery treatment combining trastuzumab, durvalumab, and FLOT for patients with HER2-positive locally advanced gastric or gastroesophageal junction cancer to see how many achieve complete tumor disappearance.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gang-Nam · NCT07911280

• Integrated genomic and clinical database for cancer biomarker discovery

  Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.

  Recruiting Samsung Medical Center · Seoul, Gang-Nam · NCT07911267

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment

  This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.

  Recruiting Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo · Bogotá, Bogota D.C. · NCT07816263

• ABBV-253 in adults with advanced solid tumors

  This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.

  Recruiting at 3 sites Phase 1 AbbVie · Grand Rapids, Michigan and 2 other locations · NCT07807956

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.